Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus

NCT07136389 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erthematosus

Interventions

DRUG: BCD-256
DRUG: BCD-256
DRUG: BCD-256
DRUG: Divozilimab
DRUG: BCD-256

Sponsor

Biocad